Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Approaches to urinary detection of prostate cancer.

Eskra JN, Rabizadeh D, Pavlovich CP, Catalona WJ, Luo J.

Prostate Cancer Prostatic Dis. 2019 Jan 17. doi: 10.1038/s41391-019-0127-4. [Epub ahead of print]

PMID:
30655600
2.

Urinary biomarkers in prostate cancer detection and monitoring progression.

Wu D, Ni J, Beretov J, Cozzi P, Willcox M, Wasinger V, Walsh B, Graham P, Li Y.

Crit Rev Oncol Hematol. 2017 Oct;118:15-26. doi: 10.1016/j.critrevonc.2017.08.002. Epub 2017 Aug 19. Review.

PMID:
28917266
3.

The role of genetic markers in the management of prostate cancer.

Choudhury AD, Eeles R, Freedland SJ, Isaacs WB, Pomerantz MM, Schalken JA, Tammela TL, Visakorpi T.

Eur Urol. 2012 Oct;62(4):577-87. doi: 10.1016/j.eururo.2012.05.054. Epub 2012 Jun 5. Review.

PMID:
22695242
4.

Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis.

Shariat SF, Scherr DS, Gupta A, Bianco FJ Jr, Karakiewicz PI, Zeltser IS, Samadi DB, Akhavan A.

Arch Esp Urol. 2011 Oct;64(8):681-94. Review. English, Spanish.

PMID:
22052751
5.

Novel diagnostic biomarkers for prostate cancer.

Madu CO, Lu Y.

J Cancer. 2010 Oct 6;1:150-77.

6.

Translational Metabolomics of Head Injury: Exploring Dysfunctional Cerebral Metabolism with Ex Vivo NMR Spectroscopy-Based Metabolite Quantification.

Wolahan SM, Hirt D, Glenn TC.

In: Kobeissy FH, editor. Brain Neurotrauma: Molecular, Neuropsychological, and Rehabilitation Aspects. Boca Raton (FL): CRC Press/Taylor & Francis; 2015. Chapter 25.

7.

Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.

Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, van Oort IM, Mulders PF, Hulsbergen-van de Kaa CA, Schalken JA.

Eur Urol. 2014 Mar;65(3):534-42. doi: 10.1016/j.eururo.2012.11.014. Epub 2012 Nov 15.

PMID:
23201468
8.

Novel biomarkers and genomic tests in prostate cancer: a critical analysis.

Falzarano SM, Ferro M, Bollito E, Klein EA, Carrieri G, Magi-Galluzzi C.

Minerva Urol Nefrol. 2015 Sep;67(3):211-31. Epub 2015 Jun 9. Review.

PMID:
26054411
9.

Urinary biomarkers for prostate cancer.

Wei JT.

Curr Opin Urol. 2015 Jan;25(1):77-82. doi: 10.1097/MOU.0000000000000133. Review.

10.

Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.

Brown LC, Ahmed HU, Faria R, El-Shater Bosaily A, Gabe R, Kaplan RS, Parmar M, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham A, Oldroyd R, Parker C, Bott S, Burns-Cox N, Dudderidge T, Ghei M, Henderson A, Persad R, Rosario DJ, Shergill I, Winkler M, Soares M, Spackman E, Sculpher M, Emberton M.

Health Technol Assess. 2018 Jul;22(39):1-176. doi: 10.3310/hta22390.

11.

Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.

Katafigiotis I, Tyritzis SI, Stravodimos KG, Alamanis C, Pavlakis K, Vlahou A, Makridakis M, Katafigioti A, Garbis SD, Constantinides CA.

BJU Int. 2012 Dec;110(11 Pt B):E688-93. doi: 10.1111/j.1464-410X.2012.11501.x. Epub 2012 Sep 28.

12.

Toward the detection of prostate cancer in urine: a critical analysis.

Truong M, Yang B, Jarrard DF.

J Urol. 2013 Feb;189(2):422-9. doi: 10.1016/j.juro.2012.04.143. Epub 2012 Sep 24. Review.

13.

Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance.

Zhao F, Olkhov-Mitsel E, van der Kwast T, Sykes J, Zdravic D, Venkateswaran V, Zlotta AR, Loblaw A, Fleshner NE, Klotz L, Vesprini D, Bapat B.

J Urol. 2017 Feb;197(2):335-341. doi: 10.1016/j.juro.2016.08.081. Epub 2016 Aug 18.

PMID:
27545574
14.

Clinical and Novel Biomarkers in the Management of Prostate Cancer.

Sanhueza C, Kohli M.

Curr Treat Options Oncol. 2018 Feb 8;19(2):8. doi: 10.1007/s11864-018-0527-z. Review.

PMID:
29423762
15.

PSA and beyond: alternative prostate cancer biomarkers.

Saini S.

Cell Oncol (Dordr). 2016 Apr;39(2):97-106. doi: 10.1007/s13402-016-0268-6. Epub 2016 Jan 20. Review.

16.

Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer.

Pandha H, Sorensen KD, Orntoft TF, Langley S, Hoyer S, Borre M, Morgan R.

BJU Int. 2012 Sep;110(6 Pt B):E287-92. doi: 10.1111/j.1464-410X.2012.11208.x. Epub 2012 May 15.

17.

Robotic-assisted minimally invasive surgery for gynecologic and urologic oncology: an evidence-based analysis.

Medical Advisory Secretariat.

Ont Health Technol Assess Ser. 2010;10(27):1-118. Epub 2010 Dec 1.

18.

Prostate cancer disparities in South Carolina: early detection, special programs, and descriptive epidemiology.

Drake BF, Keane TE, Mosley CM, Adams SA, Elder KT, Modayil MV, Ureda JR, Hebert JR.

J S C Med Assoc. 2006 Aug;102(7):241-9. Review.

PMID:
17319238
19.

Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine.

Fredsøe J, Rasmussen AKI, Thomsen AR, Mouritzen P, Høyer S, Borre M, Ørntoft TF, Sørensen KD.

Eur Urol Focus. 2018 Dec;4(6):825-833. doi: 10.1016/j.euf.2017.02.018. Epub 2017 Mar 9.

20.

Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].

Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 May.

Supplemental Content

Support Center